InvestorsHub Logo
Followers 30
Posts 4078
Boards Moderated 0
Alias Born 07/25/2007

Re: DewDiligence post# 2204

Thursday, 04/28/2022 12:15:56 PM

Thursday, April 28, 2022 12:15:56 PM

Post# of 2948
I read the guy’s dismissal of EDP-235 and it doesn’t make sense. He doesn’t state why it wouldn’t be an important drug if approved. Obviously we need efficacy data in Covid patients after safety data comes in this quarter. However, EDP-235 advantages would be significant as it would be only one pill a day and no need for a second drug to maintain Paxlovid levels high, and the drawbacks that has regarding other drugs.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News